# CITATION REPORT List of articles citing

Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodie

DOI: 10.1128/JVI.69.2.1339-1343.1995 Journal of Virology, 1995, 69, 1339-43.

Source: https://exaly.com/paper-pdf/85991779/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
236	IgA and mucosal defense. <b>1995</b> , 103, 241-6		75
235	Update on the neutralisation of animal viruses. <b>1995</b> , 5, 165-179		44
234	The common mucosal immune system for the reproductive tract: basic principles applied toward an AIDS vaccine. <b>1995</b> , 18, 23-52		17
233	Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. <b>1996</b> , 272, 104-7		419
232	New Insights into Epithelial Cell Function in Mucosal Immunity: Neutralization of Intracellular Pathogens and Excretion of antigens by IgA. <b>1996</b> , 141-149		6
231	Interaction of antigens and antibodies at mucosal surfaces. <b>1997</b> , 51, 311-40		320
230	Cellular processing limits the heterologous expression of secretory component in mammalian cells. <b>1997</b> , 246, 23-31		8
229	Protective immunity against HSV-2 in the mouse vagina. <b>1997</b> , 36, 77-92		38
228	Host-derived intracellular immunization against mouse hepatitis virus infection. <b>1997</b> , 228, 318-32		20
227	Prospects for vaccines against rotaviruses. <b>1998</b> , 8, 43-52		10
226	Viral proteins VP2, VP6, and NSP2 are strongly precipitated by serum and fecal antibodies from children with rotavirus symptomatic infection. <b>1998</b> , 56, 58-65		35
225	Effective prophylaxis of influenza A virus pneumonia in mice by topical passive immunotherapy with polyvalent human immunoglobulins or F(ab')2 fragments. <b>1998</b> , 111, 583-7		31
224	Development of antivirals against influenza. <b>1998</b> , 7, 149-65		8
223	Antigen-specific immunoglobulin-A prevents increased airway responsiveness and lung eosinophilia after airway challenge in sensitized mice. <b>1998</b> , 158, 519-25		52
222	Immunocytochemical colocalization of specific immunoglobulin A with sendai virus protein in infected polarized epithelium. <b>1998</b> , 188, 1223-9		64
221	Oral microbial ecology and the role of salivary immunoglobulin A. <b>1998</b> , 62, 71-109		301
220	Current concepts in mucosal immunity. IV. How epithelial transport of IgA antibodies relates to host defense. <b>1998</b> , 274, G614-7		26

219	Immunity to vaginal HSV-2 infection in immunoglobulin A knockout mice. <b>1998</b> , 95, 208-13		46
218	Intranasal antibody prophylaxis for protection against viral disease. <b>1999</b> , 12, 383-93		64
217	PBC and AMAwhat is the connection?. <b>1999</b> , 29, 271-6		68
216	The immunobiology of bile and biliary epithelium. <b>1999</b> , 30, 351-7		106
215	The mammary gland and neonate mucosal immunity. <b>1999</b> , 72, 143-55		54
214	Eude structurale de la protine VP6 des rotavirus et de l'inhibition de la transcription virale par des anticorps monoclonaux dirigili contre VP6. <b>1999</b> , 29, 573-580		
213	Systemic and mucosal immune responses to H1N1 influenza virus infection in pigs. <b>2000</b> , 74, 117-31		80
212	Hepatitis A virus-specific immunoglobulin A mediates infection of hepatocytes with hepatitis A virus via the asialoglycoprotein receptor. <i>Journal of Virology</i> , <b>2000</b> , 74, 10950-7	6.6	89
211	Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. <b>2000</b> , 68, 5764-70		124
<b>21</b> 0	Nasal immunization of mice with virus-like particles protects offspring against rotavirus diarrhea. Journal of Virology, <b>2000</b> , 74, 8966-71	6.6	51
209	The antiviral activity of antibodies in vitro and in vivo. <b>2001</b> , 77, 195-262		203
208	Intracellular antibody neutralizes Listeria growth. <b>2001</b> , 14, 503-12		132
207	Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. <i>Journal of Virology</i> , <b>2001</b> , 75, 5141-50	6.6	228
206	Genetic and structural determinants of virus neutralizing antibodies. <b>2001</b> , 23, 135-45		17
205	Semen from boars infected with porcine reproductive and respiratory syndrome virus (PRRSV) contains antibodies against structural as well as nonstructural viral proteins. <b>2001</b> , 81, 109-25		15
204	Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or gamma delta T cells. <b>2001</b> , 166, 7437-45		112
203	The pulmonary environment promotes Th2 cell responses after nasal-pulmonary immunization with antigen alone, but Th1 responses are induced during instances of intense immune stimulation. <b>2001</b> , 167, 4518-26		61
202	Epitope mapping porcine reproductive and respiratory syndrome virus by phage display: the nsp2 fragment of the replicase polyprotein contains a cluster of B-cell epitopes. <i>Journal of Virology</i> , <b>2001</b> , 75, 3277-90	6.6	132

201	A mucosal IgA-mediated excretory immune system in vivo. <b>2001</b> , 166, 3688-92		121
200	Modulation of immunity against herpes simplex virus infection via mucosal genetic transfer of plasmid DNA encoding chemokines. <i>Journal of Virology</i> , <b>2001</b> , 75, 569-78	6.6	75
199	Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. <b>2002</b> , 195, 113-2	:3	251
198	Multiple functions of immunoglobulin A in mucosal defense against viruses: an in vitro measles virus model. <i>Journal of Virology</i> , <b>2002</b> , 76, 10972-9	6.6	76
197	Evaluation of events occurring at mucosal surfaces: techniques used to collect and analyze mucosal secretions and cells. <b>2002</b> , 9, 753-62		5
196	Heterologous protection induced by the inner capsid proteins of rotavirus requires transcytosis of mucosal immunoglobulins. <i>Journal of Virology</i> , <b>2002</b> , 76, 8110-7	6.6	103
195	Characterization of recombinant monoclonal IgA anti-PDC-E2 autoantibodies derived from patients with PBC. <b>2002</b> , 36, 1383-92		15
194	The humoral response to live and inactivated influenza vaccines administered alone and in combination to young adults and elderly. <b>2002</b> , 24, 193-201		43
193	Characterization of recombinant monoclonal IgA anti <b>P</b> DC-E2 autoantibodies derived from patients with PBC. <b>2002</b> , 36, 1383-1392		26
192	Antibodies, viruses and vaccines. <b>2002</b> , 2, 706-13		493
192 191	Antibodies, viruses and vaccines. 2002, 2, 706-13  Mucosal immunity: some historical perspective on host-pathogen interactions and implications for mucosal vaccines. 2003, 81, 23-33		493
	Mucosal immunity: some historical perspective on host-pathogen interactions and implications for		
191	Mucosal immunity: some historical perspective on host-pathogen interactions and implications for mucosal vaccines. <b>2003</b> , 81, 23-33  Mucosal co-administration of cholera toxin and influenza virus hemagglutinin-DNA in ponies		23
191 190	Mucosal immunity: some historical perspective on host-pathogen interactions and implications for mucosal vaccines. <b>2003</b> , 81, 23-33  Mucosal co-administration of cholera toxin and influenza virus hemagglutinin-DNA in ponies generates a local IgA response. <b>2003</b> , 21, 3081-92  Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of		23 18
191 190 189	Mucosal immunity: some historical perspective on host-pathogen interactions and implications for mucosal vaccines. 2003, 81, 23-33  Mucosal co-administration of cholera toxin and influenza virus hemagglutinin-DNA in ponies generates a local IgA response. 2003, 21, 3081-92  Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. 2003, 21, 3212-8  Anti-inflammatory role for intracellular dimeric immunoglobulin a by neutralization of		23 18 145
191 190 189	Mucosal immunity: some historical perspective on host-pathogen interactions and implications for mucosal vaccines. 2003, 81, 23-33  Mucosal co-administration of cholera toxin and influenza virus hemagglutinin-DNA in ponies generates a local IgA response. 2003, 21, 3081-92  Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. 2003, 21, 3212-8  Anti-inflammatory role for intracellular dimeric immunoglobulin a by neutralization of lipopolysaccharide in epithelial cells. 2003, 18, 739-49		23 18 145 133
191 190 189 188	Mucosal immunity: some historical perspective on host-pathogen interactions and implications for mucosal vaccines. 2003, 81, 23-33  Mucosal co-administration of cholera toxin and influenza virus hemagglutinin-DNA in ponies generates a local IgA response. 2003, 21, 3081-92  Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. 2003, 21, 3212-8  Anti-inflammatory role for intracellular dimeric immunoglobulin a by neutralization of lipopolysaccharide in epithelial cells. 2003, 18, 739-49  Vaginal immunity in the HSV-2 mouse model. 2003, 22, 43-63		23 18 145 133 50

#### (2007-2005)

183	Mucosal immunoglobulins. <b>2005</b> , 206, 64-82		224
182	Production of IgA monoclonal antibody against Shiga toxin binding subunits employing nasal-associated lymphoid tissue. <b>2005</b> , 302, 125-35		13
181	Mucosal Vaccines: An Overview. <b>2005</b> , 855-874		13
180	Immunoglobulin Transport and the Polymeric Immunoglobulin Receptor. <b>2005</b> , 211-250		30
179	Biological Activities of IgA. <b>2005</b> , 267-289		19
178	Intraepithelial cell neutralization of HIV-1 replication by IgA. 2005, 174, 4828-35		63
177	Regulation of the polymeric Ig receptor by signaling through TLRs 3 and 4: linking innate and adaptive immune responses. <b>2005</b> , 175, 376-84		92
176	The function of immunoglobulin A in immunity. <b>2006</b> , 208, 270-82		431
175	Immunoglobulin A and CD8 T-cell mucosal immune defenses protect against intranasal infection with Chlamydia pneumoniae. <b>2006</b> , 63, 177-83		22
174	The IgA system: a comparison of structure and function in different species. <b>2006</b> , 37, 455-67		130
173	Immunoglobulin A antibodies against internal HIV-1 proteins neutralize HIV-1 replication inside epithelial cells. <b>2006</b> , 356, 165-70		27
172	The role of antibody-mediated immunity in defense against Mycobacterium tuberculosis: advances toward a novel vaccine strategy. <b>2006</b> , 86, 191-7		64
171	Cigarette smoke impacts immune inflammatory responses to influenza in mice. <b>2006</b> , 174, 1342-51		81
170	Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion. <i>Journal of Virology</i> , <b>2006</b> , 80, 10692-9	6.6	103
169	Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques. <i>Journal of Virology</i> , <b>2006</b> , 80, 9577-85	6.6	69
168	More about hypervirulent avian influenza: Is the world now better prepared?. 2007, 19, 78-121		4
167	Production and characterization of IgA monoclonal antibody against ovalbumin. 2007, 26, 328-32		4
166	Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. <b>2007</b> , 196, 1313-20		106

Second European Rotavirus Biology Meeting. **2007**, 2, 429-435

164	Induction of secretory immunity and memory at mucosal surfaces. <b>2007</b> , 25, 5467-84		333
163	IgA and Intestinal Homeostasis. <b>2007</b> , 221-268		9
162	Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse. <b>2007</b> , 4, 118		60
161	Unknown functions of immunoglobulins A. <b>2007</b> , 72, 485-94		7
160	Monocyte chemoattractant protein 1 contributes to an adequate immune response in influenza pneumonia. <b>2007</b> , 125, 328-36		63
159	Neutralization of animal virus infectivity by antibody. <b>2007</b> , 152, 1047-59		83
158	Induction of heterosubtypic immunity to influenza virus by intranasal immunization. <i>Journal of Virology</i> , <b>2008</b> , 82, 1350-9	6.6	124
157	Poly-immunoglobulin receptor-mediated transport of IgA into the male genital tract is important for clearance of Chlamydia muridarum infection. <b>2008</b> , 60, 405-14		23
156	Innate sensors of influenza virus: clues to developing better intranasal vaccines. 2008, 7, 1435-45		33
155	Excretion of human immunodeficiency virus type 1 through polarized epithelium by immunoglobulin A. <i>Journal of Virology</i> , <b>2008</b> , 82, 11526-35	6.6	29
154	Intracellular neutralization of shiga toxin 2 by an a subunit-specific human monoclonal antibody. <b>2008</b> , 76, 1931-9		39
153	Immune Functions and Mechanisms in the Gastrointestinal Tract. 2008, 115-141		1
152	Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. <i>Journal of Virology</i> , <b>2009</b> , 83, 5726-34	6.6	116
151	The mucosal firewalls against commensal intestinal microbes. <b>2009</b> , 31, 145-9		70
150	Investigation of the biological indicator for vaccine efficacy against highly pathogenic avian influenza (HPAI) H5N1 virus challenge in mice and ferrets. <b>2009</b> , 27, 3145-52		20
149	Intranasal administration of peptide antigens of HIV with mucosal adjuvant CpG ODN coentrapped in microparticles enhances the mucosal and systemic immune responses. <b>2009</b> , 9, 468-77		24
148	Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein. <b>2010</b> , 155, 1765-75		31

## (2011-2010)

147	Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells. <b>2010</b> , 52, 875-85		50
146	Review article: Epithelial disposition of antigen. <b>1997</b> , 11 Suppl 3, 40-4; discussion 44-6		1
145	Effect of inactivation method on the cross-protective immunity induced by whole 'killed' influenza A viruses and commercial vaccine preparations. <b>2010</b> , 91, 1450-60		55
144	Cytotoxic T cells are the predominant players providing cross-protective immunity induced by {gamma}-irradiated influenza A viruses. <i>Journal of Virology</i> , <b>2010</b> , 84, 4212-21	6.6	69
143	Polymeric IgA-secreting and mucosal homing pre-plasma cells in normal human peripheral blood. <b>2010</b> , 22, 527-40		17
142	Role of secretory immunoglobulin A and secretory component in the protection of mucosal surfaces. <b>2010</b> , 5, 817-29		85
141	Secretory IgA: arresting microbial pathogens at epithelial borders. 2010, 39, 383-406		112
140	Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. <b>2010</b> , 7, 351		106
139	Nasal mucosal administration of chitin microparticles boosts innate immunity against influenza A virus in the local pulmonary tissue. <b>2010</b> , 28, 4130-7		19
138	Molecular basis of the mucosal immune system: from fundamental concepts to advances in liposome-based vaccines. <b>2010</b> , 5, 1617-40		11
137	Bronchial secretory immunoglobulin a deficiency correlates with airway inflammation and progression of chronic obstructive pulmonary disease. <b>2011</b> , 184, 317-27		88
136	Host-recognition of pathogens and commensals in the mammalian intestine. <b>2013</b> , 358, 291-321		23
135	Immune responses to influenza virus infection. <b>2011</b> , 162, 19-30		215
134	Alzheimer∄ disease vaccines: promises and pitfalls. <b>2011</b> , 1, 969-988		1
133	Polymeric immunoglobulin receptor. <b>2011</b> , 53, 147-56		73
132	Matrix protein-specific IgA antibody inhibits measles virus replication by intracellular neutralization. <i>Journal of Virology</i> , <b>2011</b> , 85, 11090-7	6.6	21
131	Immunoglobulin A: A next generation of therapeutic antibodies?. MAbs, 2011, 3, 352-61	6.6	55
130	The human immunoglobulin A Fc receptor FcRI: a multifaceted regulator of mucosal immunity. <b>2011</b> , 4, 612-24		111

129	Evasion of influenza A viruses from innate and adaptive immune responses. <b>2012</b> , 4, 1438-76	124
128	Advances in cholangiocyte immunobiology. <b>2012</b> , 303, G1077-86	57
127	The role of nasal IgA in children vaccinated with live attenuated influenza vaccine. 2012, 30, 6794-801	71
126	The function of secretory IgA in the context of the intestinal continuum of adaptive immune responses in host-microbial mutualism. <b>2012</b> , 24, 36-42	23
125	Induction of cross-protection against influenza A virus by DNA prime-intranasal protein boost strategy based on nucleoprotein. <b>2012</b> , 9, 286	22
124	Mucosal antibody responses are directed by viral burden in children with acute influenza infection. <b>2013</b> , 7, 46-54	3
123	Immunoglobulin A: Molecular Mechanisms of Function and Role in Immune Defence. 2013, 31-60	3
122	The role of B cells and humoral immunity in Mycobacterium tuberculosis infection. <i>Advances in Experimental Medicine and Biology</i> , <b>2013</b> , 783, 225-50	86
121	Immunological assessment of influenza vaccines and immune correlates of protection. <b>2013</b> , 12, 519-36	91
120	Mucosal Immunity in the Human Reproductive Tract. <b>2013</b> , 71-110	2
119	Multi-faceted functions of secretory IgA at mucosal surfaces. <b>2013</b> , 4, 185	285
118	Development of anti-bovine IgA single chain variable fragment and its application in diagnosis of foot-and-mouth disease. <b>2014</b> , 4, 34-44	3
117	Fast vaccine design and development based on correlates of protection (COPs). 2014, 10, 1935-48	14
116	The role of B cells and humoral immunity in Mycobacterium tuberculosis infection. <b>2014</b> , 26, 588-600	88
115	Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humans. <b>2014</b> , 32, 1897-900	27
114	Antibody-Dependent Cellular Phagocytosis and Its Impact on Pathogen Control. <b>2014</b> , 29-47	3
113	Evaluation of intra- and extra-epithelial secretory IgA in chlamydial infections. <b>2014</b> , 143, 520-30	14
112	Development of universal influenza vaccines based on influenza virus M and NP genes. <b>2014</b> , 42, 251-62	43

111	Equine Influenza Infection. <b>2014</b> , 141-151.e7	7
110	Intracellular antibody immunity. <b>2014</b> , 34 Suppl 1, S30-4	17
109	Production of recombinant antibodies using bacteriophages. <b>2014</b> , 4, 91-8	17
108	Functions of Antibodies. <i>Microbiology Spectrum</i> , <b>2014</b> , 2, AID-0019-2014 8.9	88
107	Intranasal delivery of influenza rNP adjuvanted with c-di-AMP induces strong humoral and cellular immune responses and provides protection against virus challenge. <i>PLoS ONE</i> , <b>2014</b> , 9, e104824	36
106	Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin. <i>PLoS ONE</i> , <b>2015</b> , 10, e0119520	39
105	Immunoglobulin Transport and Immunoglobulin Receptors. <b>2015</b> , 349-407	7
104	Biological Activities of IgA. <b>2015</b> , 429-454	13
103	The Mucosal Immune System. <b>2015</b> , 277-291	1
102	Cross-protection against influenza virus infection by intranasal administration of nucleoprotein-based vaccine with compound 48/80 adjuvant. <b>2015</b> , 11, 397-406	15
101	Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?. <b>2016</b> , 69, 165-79	25
100	Stalking influenza by vaccination with pre-fusion headless HA mini-stem. <i>Scientific Reports</i> , <b>2016</b> , 6, 2266,6,9	90
99	Influenza H7N9 LAH-HBc virus-like particle vaccine with adjuvant protects mice against homologous and heterologous influenza viruses. <b>2016</b> , 34, 6464-6471	21
98	Specific IgA Enhances the Transcytosis and Excretion of Hepatitis A Virus. <i>Scientific Reports</i> , <b>2016</b> , 6, 21855	11
97	Oral intake of Lactobacillus rhamnosus M21 enhances the survival rate of mice lethally infected with influenza virus. <b>2016</b> , 49, 16-23	27
96	Homeostasis of the gut barrier and potential biomarkers. <b>2017</b> , 312, G171-G193	240
95	Comparison of mucosal lining fluid sampling methods and influenza-specific IgA detection assays for use in human studies of influenza immunity. <b>2017</b> , 449, 1-6	9
94	Harnessing Local Immunity for an Effective Universal Swine Influenza Vaccine. <b>2017</b> , 9,	10

93	Adjuvantation of Pulmonary-Administered Influenza Vaccine with GPI-0100 Primarily Stimulates Antibody Production and Memory B Cell Proliferation. <b>2017</b> , 5,		2
92	Nasal IgA Provides Protection against Human Influenza Challenge in Volunteers with Low Serum Influenza Antibody Titre. <i>Frontiers in Microbiology</i> , <b>2017</b> , 8, 900	5.7	60
91	Colocalization of intracellular specific IgA (icIgA) with influenza virus in patients' nasopharyngeal aspirate cells. <b>2018</b> , 252, 8-14		3
90	Efficacy of a Recombinant Turkey Herpesvirus AI (H5) Vaccine in Preventing Transmission of Heterologous Highly Pathogenic H5N8 Clade 2.3.4.4b Challenge Virus in Commercial Broilers and Layer Pullets. <i>Journal of Immunology Research</i> , <b>2018</b> , 2018, 3143189	4.5	7
89	Salivary biomarkers for the diagnosis and monitoring of neurological diseases. 2018, 41, 63-87		78
88	Host Immune Response to Influenza A Virus Infection. <b>2018</b> , 9, 320		164
87	The Role of the Polymeric Immunoglobulin Receptor and Secretory Immunoglobulins during Mucosal Infection and Immunity. <b>2018</b> , 10,		77
86	Intranasal inactivated influenza vaccines for the prevention of seasonal influenza epidemics. <b>2018</b> , 17, 687-696		12
85	Localization and Regulation of Polymeric Ig Receptor in Healthy and Diseased Human Kidney. <b>2019</b> , 189, 1933-1944		8
84	Mutation S110L of H1N1 Influenza Virus Hemagglutinin: A Potent Determinant of Attenuation in the Mouse Model. <b>2019</b> , 10, 132		3
83	IgA: Structure, Function, and Developability. <b>2019</b> , 8,		50
82	Age-related changes in the morphology and the distribution of IgA and IgG in the pharyngeal tonsils of yaks (Bos grunniens). <b>2019</b> , 280, 214-222		1
81	Challenges for the Newborn Immune Response to Respiratory Virus Infection and Vaccination. <b>2020</b> , 8,		5
80	Comparative Analyses of the Antiviral Activities of IgG and IgA Antibodies to Influenza A Virus M2 Protein. <b>2020</b> , 12,		2
79	Protein transduction domain-mediated influenza NP subunit vaccine generates a potent immune response and protection against influenza virus in mice. <b>2020</b> , 9, 1933-1942		5
78	Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. <b>2020</b> , 33,		32
77	Potential Role of Nonneutralizing IgA Antibodies in Cross-Protective Immunity against Influenza A Viruses of Multiple Hemagglutinin Subtypes. <i>Journal of Virology</i> , <b>2020</b> , 94,	6.6	10
76	B Cell Activation and Response Regulation During Viral Infections. <b>2020</b> , 33, 294-306		15

## (2001-2021)

75	IgA dominates the early neutralizing antibody response to SARS-CoV-2. <b>2021</b> , 13,	405
74	When Therapeutic IgA Antibodies Might Come of Age. <b>2021</b> , 106, 9-19	11
73	M2e-Based Influenza Vaccines with Nucleoprotein: A Review. <b>2021</b> , 9,	4
72	Streptococcus pneumoniae colonisation associates with impaired adaptive immune responses against SARS-CoV-2.	2
71	The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies. <b>2021</b> , 22,	9
70	Engaging the AIClass Antibody: Variable-Heavy (VH) region influencing IgA1&2 engagement of FcRI and superantigen proteins G, A, and L.	3
69	Highly Specific Memory B Cells Generation after the 2nd Dose of BNT162b2 Vaccine Compensate for the Decline of Serum Antibodies and Absence of Mucosal IgA. <i>Cells</i> , <b>2021</b> , 10,	19
68	Regulation of the Mucosal IgA System. <b>2007</b> , 111-143	2
67	Biological Functions of IgA. <b>2007</b> , 144-172	6
66	Protection of Mucosal Epithelia by IgA: Intracellular Neutralization and Excretion of Antigens. <b>2007</b> , 173-182	5
65	The Mucosal B-Cell System. <b>2008</b> , 33-76	1
64	Interference with virus and bacteria replication by the tissue specific expression of antibodies and interfering molecules. <i>Advances in Experimental Medicine and Biology</i> , <b>1999</b> , 473, 31-45	2
63	Delivery systems and adjuvants for vaccination against HIV. <b>2000</b> , 89, 227-37	3
62	Host responses to respiratory virus infection and immunization. <b>1999</b> , 236, 191-214	29
61	Role of mucosal antibodies in viral infections. <b>2001</b> , 260, 201-28	18
60	Mechanisms of virus neutralization by antibody. <b>2001</b> , 260, 87-108	43
59	A model for neutralization of viruses based on antibody coating of the virion surface. <b>2001</b> , 260, 109-43	81
58	The role of the antibody response in influenza virus infection. <b>2001</b> , 260, 171-90	153

57	Adaptive immunity in the gastrointestinal tract. <b>2001</b> , 35-53		1
56	The polymeric immunoglobulin receptor. <b>1998</b> , 51-62		1
55	Parainfluenza Viruses. <b>2010</b> , 2195-2199		1
54	Structure and Function of the Polymeric Immunoglobulin Receptor in Epithelial Cells. <b>1996</b> , 151-166		2
53	Mucosal Immunity to Viruses. <b>2005</b> , 799-813		8
52	MUCOSAL IMMUNITY OF THE GENITAL TRACT. <b>2000</b> , 97-122		1
51	Equine Influenza Infection. <b>2007</b> , 124-134		6
50	Occupancy and mechanism in antibody-mediated neutralization of animal viruses. 2002, 83, 2091-2108		212
49	IgA dominates the early neutralizing antibody response to SARS-CoV-2.		54
48	Functions of Antibodies. 23-48		7
48	Functions of Antibodies. 23-48  Intestinal Immunoglobulin A: Role in Host Defense. 95-112		2
47	Intestinal Immunoglobulin A: Role in Host Defense. 95-112  Specific-antibody-secreting cells in the rectums and genital tracts of nonhuman primates following	6.6	2
47 46	Intestinal Immunoglobulin A: Role in Host Defense. 95-112  Specific-antibody-secreting cells in the rectums and genital tracts of nonhuman primates following vaccination. 1998, 66, 5889-96  Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric	6.6	2 58
47 46 45	Intestinal Immunoglobulin A: Role in Host Defense. 95-112  Specific-antibody-secreting cells in the rectums and genital tracts of nonhuman primates following vaccination. 1998, 66, 5889-96  Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus. <i>Journal of Virology</i> , 1995, 69, 6678-86  Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against		2 58 93
47 46 45 44	Intestinal Immunoglobulin A: Role in Host Defense. 95-112  Specific-antibody-secreting cells in the rectums and genital tracts of nonhuman primates following vaccination. 1998, 66, 5889-96  Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus. <i>Journal of Virology</i> , 1995, 69, 6678-86  Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. <i>Journal of Virology</i> , 1996, 70, 6418-24  Epithelial cell polarization is a determinant in the infectious outcome of immunoglobulin	6.6	2 58 93 71
47 46 45 44 43	Intestinal Immunoglobulin A: Role in Host Defense. 95-112  Specific-antibody-secreting cells in the rectums and genital tracts of nonhuman primates following vaccination. 1998, 66, 5889-96  Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus. <i>Journal of Virology</i> , 1995, 69, 6678-86  Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. <i>Journal of Virology</i> , 1996, 70, 6418-24  Epithelial cell polarization is a determinant in the infectious outcome of immunoglobulin A-mediated entry by Epstein-Barr virus. <i>Journal of Virology</i> , 1997, 71, 519-26  Interference of coronavirus infection by expression of immunoglobulin G (IgG) or IgA	6.6	2 58 93 71 63

## (2021-2002)

39	Inhibition of rotavirus replication by a non-neutralizing, rotavirus VP6-specific IgA mAb. <i>Journal of Clinical Investigation</i> , <b>2002</b> , 109, 1203-13	15.9	129
38	Human serum immunoglobulin counteracts rotaviral infection in Caco-2 cells. <b>1996</b> , 40, 881-7		8
37	Heterosubtypic antiviral activity of hemagglutinin-specific antibodies induced by intranasal immunization with inactivated influenza viruses in mice. <i>PLoS ONE</i> , <b>2013</b> , 8, e71534	3.7	13
36	Comparison of antiviral activity between IgA and IgG specific to influenza virus hemagglutinin: increased potential of IgA for heterosubtypic immunity. <i>PLoS ONE</i> , <b>2014</b> , 9, e85582	3.7	54
35	CURRENT APPROACHES TO UNIVERSAL VACCINE AGAINST INFLUENZA VIRUS. <i>Russian Journal of Infection and Immunity</i> , <b>2016</b> , 6, 117-132	0.4	2
34	Early supplementation of Saccharomyces cerevisiae boulardii CNCM I-1079 in newborn dairy calves increases IgA production in the intestine at 1 week of age. <i>Journal of Dairy Science</i> , <b>2020</b> , 103, 8615-862	8 <sup>1</sup>	10
33	IgA and Reproductive Tract Immunity. <b>2007</b> , 291-320		
32	A Gut Reaction: Aging Affect Gut-Associated Immunity. <b>2009</b> , 175-222		
31	Rotaviruses.		
30	Interference of coronavirus infection by expression of IgG or IgA virus neutralizing antibodies. <i>Advances in Experimental Medicine and Biology</i> , <b>1998</b> , 440, 665-74	3.6	
29	Presentation of Neutralizing Antibodies in Single- or Pooled-Convalescent Immune Plasma from Donors to Prevent the Current SARS-CoV-2 Pandemic. <b>2020</b> , 1, 4-15		
28	Functions of Antibodies. <i>Microbiology Spectrum</i> , <b>2014</b> , 2, 1-17	8.9	38
27	Virus neutralisation by intracellular antibodies. Seminars in Cell and Developmental Biology, 2021,	7.5	О
26	Streptococcus pneumoniae colonization associates with impaired adaptive immune responses against SARS-CoV-2 <i>Journal of Clinical Investigation</i> , <b>2022</b> ,	15.9	2
25	Respiratory Mucosal Immunity: Kinetics of Secretory Immunoglobulin A in Sputum and Throat Swabs From COVID-19 Patients and Vaccine Recipients <i>Frontiers in Microbiology</i> , <b>2022</b> , 13, 782421	5.7	О
24	Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?. <i>MAbs</i> , <b>2022</b> , 14, 2031483	6.6	2
23	High prevalence of intrathecal IgA synthesis in multiple sclerosis patients <i>Scientific Reports</i> , <b>2022</b> , 12, 4247	4.9	
22	Immunoglobulin A Mucosal Immunity and Altered Respiratory Epithelium in Cystic Fibrosis <i>Cells</i> , <b>2021</b> , 10,	7.9	2

21	Variable-heavy (VH) families influencing IgA1&2 engagement to the antigen, FcRI and superantigen proteins G, A, and L <i>Scientific Reports</i> , <b>2022</b> , 12, 6510	4.9	О
20	Image_1.TIF. <b>2019</b> ,		
19	lmage_2.TIF. <b>2019</b> ,		
18	Image_3.TIF. <b>2019</b> ,		
17	Image_4.TIF. <b>2019</b> ,		
16	Biological and Immune Responses to Current Anti-SARS-CoV-2 mRNA Vaccines beyond Anti-Spike Antibody Production. <i>Journal of Immunology Research</i> , <b>2022</b> , 2022, 1-7	4.5	O
15	SARS-CoV-2-neutralizing humoral IgA response occurs earlier but modest and diminishes faster compared to IgG response		0
14	A Dual Adjuvant System for Intranasal Boosting of Local and Systemic Immunity for Influenza Vaccination. <b>2022</b> , 10, 1694		O
13	SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response.		1
12	HIV-1 Neutralizing Antibodies in the Genital and Respiratory Tracts of Mice Intranasally Immunized with Oligomeric gp160. <b>1998</b> , 160, 2000-2012		19
11	Mucosal Immunity to Influenza Without IgA: An IgA Knockout Mouse Model. <b>1999</b> , 162, 2530-2537		26
10	Generation of Polymeric Immunoglobulin Receptor-Deficient Mouse with Marked Reduction of Secretory IgA. <b>1999</b> , 163, 5367-5373		20
9	Intracellular immunoglobulin A ( icIgA ) in protective immunity and vaccines.		0
8	Long-term respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination.		O
7	Long-term respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination.		0
6	Antiviral neutralizing antibodies: from in vitro to in vivo activity.		O
5	Aluminum-based metalorganic framework nanoparticles as pulmonary vaccine adjuvants. <b>2023</b> , 21,		О
4	Immunity in SARS-CoV-2 Infection: Clarity or Mystery? A Broader Perspective in the Third Year of a Worldwide Pandemic. <b>2023</b> , 71,		O

#### CITATION REPORT

Enhanced mucosal immune responses and reduced viral load in the respiratory tract of ferrets to intranasal lipid nanoparticle-based SARS-CoV-2 proteins and mRNA vaccines. 2023, 21,

Mucosal immunization with Ad5-based vaccines protects Syrian hamsters from challenge with omicron and delta variants of SARS-CoV-2. 14,

Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG. 2023, 15, 912